US 12,084,499 B2
SIRP-α binding proteins and methods of use thereof
Mahan Abbasian, San Diego, CA (US); Henry H. Chan, Poway, CA (US); Laure Escoubet, San Diego, CA (US); Gustavo Fenalti, San Diego, CA (US); Kandasamy Hariharan, San Diego, CA (US); Monica Wai Ling Leung, San Diego, CA (US); Konstantinos Mavrommatis, Concord, CA (US); David P. Mikolon, San Diego, CA (US); Heather K. Raymon, San Diego, CA (US); Carlo Steven Santos, San Diego, CA (US); Jeonghoon Sun, San Francisco, CA (US); and Christina Valerie Trout, San Diego, CA (US)
Assigned to Celgene Corporation, Summit, NJ (US)
Filed by Celgene Corporation, Summit, NJ (US)
Filed on Feb. 1, 2023, as Appl. No. 18/162,879.
Application 18/162,879 is a division of application No. 16/582,813, filed on Sep. 25, 2019, granted, now 11,591,390.
Application 16/582,813 is a continuation of application No. PCT/US2019/052604, filed on Sep. 24, 2019.
Claims priority of provisional application 62/853,997, filed on May 29, 2019.
Claims priority of provisional application 62/737,782, filed on Sep. 27, 2018.
Prior Publication US 2024/0034789 A1, Feb. 1, 2024
Int. Cl. C07K 16/28 (2006.01)
CPC C07K 16/2803 (2013.01) [C07K 16/2863 (2013.01); C07K 16/2896 (2013.01); C07K 2317/34 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/732 (2013.01); C07K 2317/92 (2013.01)] 31 Claims
 
1. A method of treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of an antibody or antigen binding fragment thereof that binds to human SIRPα, wherein the antibody or antigen binding fragment thereof comprises:
(a) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having the amino acid sequence of SEQ ID NO:67; and
(b) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having the amino acid sequence of SEQ ID NO:80.